In 2017, Cladribine Tablets (MAVENCLAD®) received its marketing authorization from the European Medicines Agency (EMA) for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS). In a Network Meta-Analysis (NMA) conducted by Siddiqui et al in 2017, the credible intervals for Cladribine Tablets, compared to alemtuzumab, fingolimod, and natalizumab, overlapped for key efficacy endpoints. Due to no statistical differences demonstrated in the NMA, the aim of this analysis was to assume comparable efficacy among these Disease Modifying Treatments (DMTs) and conduct a Cost Minimization Analysis (CMA) of Cladribine Tablets against these alternatives in a National Health Service (NHS) United Kingdom (U.K) setting.
Authors: Harty G, Treharne C, Budhia S, Wong SL
To find out more about this poster you can register to download it here after the ISPOR event.